Lead sponsor
Alector Inc.
7 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
7
Trials led
0
Ongoing
892
Total enrollment
185
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
3
Phase 2
3
Phase 3
1
Trials by status
Completed
5
Terminated
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's DiseaseStudy partner/caregiver requiredPh 2Terminated197
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)At-risk or symptomatic FTD · GRN mutation requiredPh 3Terminated119
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) MutationAge 18-80Ph 1Completed64
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)GRN/C9orf72 mutation requiredPh 2Completed33